Liquidia Co. (NASDAQ:LQDA) Position Lifted by DMC Group LLC

DMC Group LLC raised its stake in Liquidia Co. (NASDAQ:LQDA) by 36.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 13,883 shares of the company’s stock after purchasing an additional 3,725 shares during the period. DMC Group LLC’s holdings in Liquidia were worth $139,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Quest Partners LLC acquired a new position in shares of Liquidia in the 2nd quarter worth approximately $27,000. Hilltop National Bank bought a new stake in Liquidia during the second quarter valued at $33,000. Whitcomb & Hess Inc. raised its holdings in shares of Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after purchasing an additional 1,074 shares during the period. Deuterium Capital Management LLC acquired a new stake in shares of Liquidia during the second quarter worth $120,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Liquidia by 398.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,039 shares of the company’s stock worth $156,000 after buying an additional 10,421 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Stock Performance

Shares of LQDA opened at $11.14 on Friday. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99. The stock’s fifty day moving average is $10.41 and its 200-day moving average is $11.92. The firm has a market capitalization of $851.25 million, a price-to-earnings ratio of -7.14 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The company had revenue of $3.66 million for the quarter, compared to analyst estimates of $7.92 million. Analysts forecast that Liquidia Co. will post -1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LQDA. HC Wainwright lowered their price objective on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Scotiabank assumed coverage on Liquidia in a research report on Wednesday. They set a “sector outperform” rating and a $30.00 price target on the stock. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Bank of America dropped their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Liquidia in a research note on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Insider Activity at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares in the company, valued at $2,304,025.13. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the transaction, the general counsel now owns 486,048 shares in the company, valued at approximately $5,399,993.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares in the company, valued at $2,304,025.13. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,858 shares of company stock worth $228,724 over the last quarter. 31.60% of the stock is currently owned by company insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).